公开(公告)号：US20240335394A1

公开(公告)日：2024-10-10

申请号：US18579221

申请日：2022-07-15

申请人： Ludwig Institute for Cancer Research Ltd

发明人： Kellen Olszewski ,  Joshua D. Rabinowitz ,  Hahn Kim

IPC分类号： A61K31/045 ,  A61K9/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K31/045 ,  A61K9/0053 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827

摘要： Provided herein are methods of using methanol, or a prodrug thereof, in therapy, e.g., for promoting an immune response, treating cancer, enhancing an immunotherapy and/or treating immune dysfunction. Also provided herein are methanol prodrugs of the following structural formula: Formula (I), or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., R, X, R2, n) are as described herein.

公开(公告)号：US20240316092A1

公开(公告)日：2024-09-26

申请号：US18493056

申请日：2023-10-24

申请人： Ionis Pharmaceuticals, Inc. ,  Ludwig Institute For Cancer Research

发明人： Huynh-Hoa Bui ,  Don W. Cleveland ,  Ze'ev Melamed

IPC分类号： A61K31/7125 ,  C12N15/113

CPC分类号： A61K31/7125 ,  C12N15/113 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/344 ,  C12N2310/346 ,  C12N2310/351

摘要： Provided are compounds, methods, and pharmaceutical compositions for increasing the amount or activity of STMN2 RNA in a cell or animal, and in certain embodiments increasing the amount of STMN2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include ataxia, neuropathy, synaptic dysfunction, deficits in cognition, and decreased longevity. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and dementia with Lewy bodies (DLB).

公开(公告)号：US20240207319A1

公开(公告)日：2024-06-27

申请号：US18557978

申请日：2022-05-04

申请人： Ludwig Institute for Cancer Research Ltd ,  Centre Hospitalier Universitaire Vaudois ,  UNIVERSITY OF LAUSANNE

发明人： George Coukos ,  Melita Irving ,  Angel De Jesus Corria Osorio ,  Vincent Zoete

IPC分类号： A61K35/17 ,  A61K9/00 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K14/535 ,  C07K14/55 ,  C07K16/28 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K9/0019 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/4632 ,  A61K39/464411 ,  A61K39/464439 ,  A61K39/46444 ,  A61K39/464486 ,  A61K45/06 ,  A61P35/00 ,  C07K14/535 ,  C07K14/55 ,  C07K16/2818 ,  C12N5/0636 ,  A61K2239/13 ,  A61K2239/31

摘要： The present disclosure relates to methods and compositions to confer and/or increase immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific genetically-modified lymphocytes such as human T lymphocytes. The disclosure provides compositions comprising genetically-modified lymphocytes that express at least two transgene(s) having the ability to modulate the immune system and the innate and adaptive immune response.

公开(公告)号：US20240096441A1

公开(公告)日：2024-03-21

申请号：US18516098

申请日：2023-11-21

申请人： Ludwig Institute for Cancer Research Ltd

发明人： Bing Ren ,  Miao Yu ,  Rongxin Fang

IPC分类号： G16B5/00 ,  C12N15/10

CPC分类号： G16B5/00 ,  C12N15/1065

摘要： Methods and kits for genome-wide identification of chromatin interactions in a cell are provided.

公开(公告)号：US11833168B2

公开(公告)日：2023-12-05

申请号：US16973652

申请日：2019-06-14

申请人： Ionis Pharmaceuticals, Inc. ,  Ludwig Institute For Cancer Research

发明人： Huynh-Hoa Bui ,  Don W. Cleveland ,  Ze'ev Melamed

IPC分类号： C12N15/11 ,  A61K31/7125 ,  C12N15/113

CPC分类号： A61K31/7125 ,  C12N15/113 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/344 ,  C12N2310/346 ,  C12N2310/351

摘要： Provided are compounds, methods, and pharmaceutical compositions for increasing the amount or activity of STMN2 RNA in a cell or animal, and in certain embodiments increasing the amount of STMN2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include ataxia, neuropathy, synaptic dysfunction, deficits in cognition, and decreased longevity. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and dementia with Lewy bodies (DLB).

公开(公告)号：US20230365933A1

公开(公告)日：2023-11-16

申请号：US18246710

申请日：2021-09-28

申请人： SOCIETE DES PRODUITS NESTLE S.A. ,  LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

发明人： NICOLA VANNINI ,  MUKUL GIROTRA ,  GEORGE COUKOS

IPC分类号： C12N5/0789 ,  A61K35/28

CPC分类号： C12N5/0647 ,  A61K35/28 ,  C12N2500/38 ,  C12N2500/40 ,  C12N2501/999

摘要： Use of a composition comprising a combination of a NAD+ precursor, preferably Nicotinamide Riboside and Vitamin B12 for increasing stem cell function in a population of haematopoietic stem and/or progenitor cells (HSPCs).

公开(公告)号：US20230330225A1

公开(公告)日：2023-10-19

申请号：US18187367

申请日：2023-03-21

申请人： AGENUS INC. ,  LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. ,  MEMORIAL SLOAN-KETTERING CANCER CENTER

发明人： Marc VAN DIJK ,  Cornelia Anne MUNDT ,  Gerd RITTER ,  David SCHAER ,  Jedd David WOLCHOK ,  Taha MERGHOUB ,  Nicholas S. WILSON ,  David Adam SAVITSKY ,  Mark Arthur FINDEIS ,  Dennis J. UNDERWOOD ,  Jean-Marie CUILLEROT ,  Igor Proscurshim ,  Olga SHEBANOVO

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61P11/00 ,  A61P35/04

CPC分类号： A61K39/39558 ,  C07K16/2818 ,  A61P11/00 ,  A61P35/04 ,  A61K2039/505

摘要： The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

公开(公告)号：US20230287094A1

公开(公告)日：2023-09-14

申请号：US17951440

申请日：2022-09-23

申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH, LTD.

发明人： Jacques VAN SNICK ,  Catherine UYTTENHOVE

IPC分类号： C07K16/22 ,  A61K47/68 ,  A61P35/04 ,  A61P35/00 ,  A61K39/395 ,  C07K16/30 ,  G01N33/574

CPC分类号： C07K16/22 ,  A61K39/3955 ,  A61K47/6845 ,  A61P35/00 ,  A61P35/04 ,  C07K16/30 ,  G01N33/57488 ,  A61K2039/505

摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-β3) are provided, particularly recognizing human and mouse TGF-β3, particularly antibodies and fragments that do not recognize or bind TGF-β1 or TGF-β2. Particular antibodies are provided which specifically recognize and neutralize TGF-β3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody MTGF-β3-9, MTGF-β3-12, MTGF-β3-16, MTGF-β3-17 and MTGF-β3-19, whose sequences are provided herein.

公开(公告)号：US20230167186A1

公开(公告)日：2023-06-01

申请号：US17930542

申请日：2022-09-08

申请人： AGENUS INC. ,  Memorial Sloan-Kettering Cancer Center ,  Ludwig Institute for Cancer Research Ltd.

发明人： Marc VAN DIJK ,  Ekaterina V. BREOUS-NYSTROM ,  Volker SEIBERT ,  Gerd RITTER ,  David SCHAER ,  Daniel HIRSCHHORN-CYMERMAN ,  Taha MERGHOUB ,  Hao TANG ,  David A. SAVITSKY ,  Jeremy WAIGHT ,  Nicholas S. WILSON

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  G01N33/68

CPC分类号： C07K16/2878 ,  C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  G01N33/6863 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/70 ,  C07K2317/71 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92 ,  A61K2039/505

摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

公开(公告)号：US20230076949A1

公开(公告)日：2023-03-09

申请号：US17929033

申请日：2021-02-10

申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

发明人： Chunxiao SONG ,  Yibin LIU

IPC分类号： C12Q1/6827

摘要： The present disclosure provides a bisulfite-free, long-read, base-resolution method named long-read TAPS (lrTAPS) for detecting 5-Methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) in a nucleic acid sequence. lrTAPS comprises mild enzymatic and chemical reactions to detect 5mC and 5hmC, the two major epigenetic marks found in the mammalian genome, quantitatively at base-resolution without affecting unmodified cytosine.